SCHEMBL259393

SCHEMBL259393

Cc1cccc(NC(=O)Cc2ccccn2)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.67
RAB9A P51151 2/20 0.67
CYP1A2 P05177 1/20 0.61
CYP3A4 P08684 1/20 0.61
CYP2C19 P33261 1/20 0.61
HPGD P15428 4/20 0.60
ALDH1A1 P00352 2/20 0.60
DRD2 P14416 4/20 0.56
DRD4 P21917 3/20 0.56
DRD3 P35462 3/20 0.56
KDM4E B2RXH2 1/20 0.56
MAPK1 P28482 1/20 0.56
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
CA5A P35218 1/20 0.55
CA7 P43166 1/20 0.55
CA5B Q9Y2D0 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
TP53 P04637 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2028409 0.84 CA1 (0.69) NPC1RAB9ADRD2MAPK1CA1
SCHEMBL2134679 0.83 RAB9A (0.67) NPC1RAB9ACYP1A2CYP3A4CYP2C19
SCHEMBL20914376 0.80 RAB9A (0.73) NPC1RAB9ACYP1A2CYP3A4CYP2C19
SCHEMBL10979356 0.80 MEN1 (0.55) NPC1RAB9ACYP1A2CYP3A4CYP2C19
SCHEMBL10576461 0.78 CA1 (0.67) NPC1RAB9AHPGDALDH1A1DRD2
SCHEMBL259620 0.78 ALDH1A1 (0.76) NPC1RAB9AHPGDALDH1A1KDM4E
SCHEMBL18546011 0.78 CA1 (0.66) NPC1RAB9AALDH1A1DRD2MAPK1
SCHEMBL6436243 0.78 CA1 (0.59) NPC1RAB9AALDH1A1DRD2KDM4E
SCHEMBL2355851 0.77 SMN1; SMN2 (0.47) NPC1RAB9ACYP3A4DRD2MAPK1
SCHEMBL21348789 0.77 L3MBTL1 (0.61) NPC1RAB9ACYP1A2CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A NPC1 1963/4885RAB9A 613/4885CYP1A2 3921/4885
US-20070037805-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A NPC1 1963/4885RAB9A 613/4885CYP1A2 3921/4885
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A NPC1 1963/4885RAB9A 613/4885CYP1A2 3921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.